The clinical significance of thrombospondin-1 in systemic lupus erythematosus
10.3760/cma.j.issn.1007-7480.2017.09.005
- VernacularTitle:血小板反应蛋白-1在系统性红斑狼疮中的临床意义
- Author:
Meng ZHANG
1
;
Yang MENG
;
Yuzhou GAN
;
Xiaozhen ZHAO
;
Yan WANG
;
Xiaolin SUN
;
Xuewu ZHANG
Author Information
1. 473009,郑州大学附属南阳市中心医院肾病风湿免疫科
- Keywords:
Lupus erythematosus,systemic;
Thrombospondin-1
- From:
Chinese Journal of Rheumatology
2017;21(9):601-604
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical significance of serum thrombospondin-1 (TSP-1) in systemic lupus erythematosus (SLE), and explore its possible involvement in SLE pathogenesis. Methods One hundred and thirty-eight patients diagnosed with SLE, including 124 cases of females and 14 males, as well as 60 healthy controls were recruited into this study. Enzyme-linked immunosorbent assay (ELISA) was used to determine serum TSP-1 expression level between the two groups. Spearman correlation analysis method was used to analyze the correlation between TSP-1 level of complement 3, complement 4, anti-double-stranded DNA, Rheumatoid factor and systemic lupus erythematosus disease activity index (SLEDAI). Results TSP-1 level in healthy control group was much higher than that in SLE patients. TSP-1 serum levels in SLE patients was positively correlated with complement 3 (r=0.386, P<0.01), complement 4 (r=0.301, P<0.01), and negatively correlated with anti-double-stranded DNA (r=-0.221, P=0.009), RF (r=-0.186, P=0.029) and SLEDAI (r=-0.273, P=0.001). Conclusion TSP-1 may play an immune-regulatory role in the development of SLE by inhibiting inflammation and autoantibody production. It could become a potential therapeutic target for the treatment of SLE.
